$412.5 million! Mabwell Announces Exclusive Licensing Agreement with DISC MEDICINE, INC. for Innovative Drug Candidates of Hematologic Diseases

---

SAN DIEGO, Jan. 20, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with the layout of whole industry chain, announced its wholly-owned subsidiary Mabwell Therapeutics has entered into an agreement with DISC MEDICINE, INC. ("Disc") about 9MW3011 (R&D code in the US: MWTX-001, MWTX-002 & MWTX-003). Under the terms of the agreement, Disc will obtain exclusive rights to develop and commercialize 9MW3011 discovered by Mabwell, in the United States, Europe, and other territories outside of Great China and Southeast Asia. Mabwell can obtain a total of up to $412.5 million of down payment and milestone payment, and can also obtain the royalty of close to two digit percentage of net sales of licensed products, of which Disc will pay a one-time non refundable down payment of $10million to Mabwell. 9MW3011 has been approved by NMPA and FDA to carry out clinical trials in China and the United States respectively.

"We've been expanding global business actively and I'm so excited that Mabwell reaches an exclusive license agreement with Disc for 9MW3011 which is an innovative drug independently research & developed by Mabwell Therapeutics," said Datao Liu, Co-founder & CEO of Mabwell, "Disc has rich clinical and preclinical experience in the field of hematological diseases. It will further accelerate the clinical progress of this variety in the world and fulfilling unmet clinical need for patients of hematologic diseases."

"Disc has built deep expertise in the role of iron homeostasis in hematologic disorders, and I am thrilled to expand our portfolio with these highly complementary antibody programs." said John Quisel, J.D., Ph.D., Chief Executive Officer and President of Disc. "We are delighted to be partnering with Mabwell, a company with a strong antibody technology platform. This program is in perfect alignment with our strategy and we look forward to advancing MWTX-003 into phase 1 studies later this year."

The proposed indications of 9MW3011 include a variety of diseases classified as rare in different regions of the world, such as β-thalassemia, polycythemia vera. There are no mature and effective macromolecular drugs for the relevant indications so far. 9MW3011 is expected to be qualified as an orphan drug in the future and become the first-in-class macromolecular drug to regulate iron homeostasis in vivo.

About Mabwell

Mabwell (688062.SH), an innovation-driven biopharmaceutical company, has the whole industrial chain of R&D, manufacturing, and commercialization. We provide more effective and accessible therapy and innovative medicines to fulfill global medical needs. Since 2017, an advanced R&D system which covers target discovery, early discovery, druggability, preclinical, clinical research and manufacturing transformation was established. Mabwell has 14 pipeline products in different R&D stages based on a world-class and state-of-the-art R&D engine, including 10 novel drug candidates and 4 biosimilars. We focus on the therapeutic areas of auto-immune diseases, oncology, metabolic disorders, ophthalmologic diseases and infectious diseases, etc. Of these, 1 product has been approved and commercialized, 2 products have been filed for MA approval, 3 products are in pivotal trials. We have also undertaken 1 national major scientific and technological special project for "Significant New Drugs Development", 2 projects for National Key R&D Programmes, and several provincial and municipal science and technological innovation projects. Mabwell's Taizhou factory possesses robust in-house manufacturing capability compliant with international GMP standards regulated by the NMPA, FDA and EMA, and has passed the EU QP Audit. The large-scale manufacturing base located in Shanghai is under construction. Our mission is "Explore Life, Benefit Health" and our vision is "Innovation, from ideas to reality". For more information, please visit www.mabwell.com.

About Disc

Disc Medicine is a clinical-stage biopharmaceutical company committed to discovering, developing, and commercializing novel treatments for patients who suffer from serious hematologic diseases. We are building a portfolio of innovative, first-in-class therapeutic candidates that aim to address a wide spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis. For more information, please visit www.discmedicine.com.

Forward-Looking Statements

This press release contains forward-looking statements including, but not limited to, the potential safety, efficacy, regulatory review or approval and commercial success of our product candidates and those relating to the Company's product development, clinical studies, clinical and regulatory milestones and timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. "Forward-looking statements" are statements that are not historical facts and involve a number of risks and uncertainties, which may cause actual results to be materially different from any future results expressed or implied in the forward-looking statements. These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would," and similar expressions and the negatives of those terms.

Forward-looking statements are based on the Company's current expectations and assumptions. Forward-looking statements are subject to a number of risks, uncertainties, and other factors, many of which are beyond the Company's control, including, but not limited to: environment; politic; economy; society; legislation; our dependence on our product candidates, most of which are still in preclinical or various stages of clinical development; our reliance on third-party vendors, such as contract research organizations and contract manufacturing organizations; the uncertainties inherent in clinical testing; our ability to complete required clinical trials for our product candidates and obtain approval from regulatory authorities for our product candidates; our ability to protect our intellectual property; the potential impact of COVID-19; the loss of any executive officers or key personnel. In case one or more of these risks or uncertainties deteriorate, or any assumptions are incorrect, the actual results may be seriously inconsistent with the stated results.

The Company cautions all the persons not to place undue reliance on any such forward-looking statements, which speaks only as of the date of this press release. The Company disclaims any obligation, except as specifically required by law and the rules of the applicable Stock authority to publicly update or revise any such statements to reflect any change in expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. All forward-looking descriptions, figures and assumptions in this press release are applicable to this statement.

 

View original content:https://www.prnewswire.com/news-releases/412-5-million-mabwell-announces-exclusive-licensing-agreement-with-disc-medicine-inc-for-innovative-drug-candidates-of-hematologic-diseases-301726440.html


Source: Mabwell Related Stocks: Shanghai:688062 Shanghai:688062.SS

Related News

menu
menu